Download pdf - Hépatite C épidémiologie.pdf

13 janv. 2011

LiverCenter

www.slideshare.net/

DU 2011 Hépatites Virales

jeudi 13 janvier 2011

http://www.slideshare.net/.../tp-traitement-hcv-du-2009-presentation

http://www.slideshare.net/.../tp-traitement-hcv-du-2009-presentation

13 janv. 2011

1945-2009: 200,000 Publications in Cirrhosis or Hepatitis


13 janv. 2011


0

25 000

50 000

75 000

100 000

45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89 90-94 95-99 95-04 05-09


13 janv. 2011


0

25 000

50 000

75 000

100 000

45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89 90-94 95-99 95-04 05-09

1 Publication per 15 minutes in 2010


13 janv. 2011

Thruth survival of Hepatologists’ conclusions

Poynard Ann Med 2002, Plos One 2010

n=474


13 janv. 2011

LiverCenter

Epidémiologie et histoire naturelle de l’hépatite virale C

DU 2011Thierry PoynardGroupe Hospitalier Pitié Salpêtrière


13 janv. 2011

Cancer

F4

HCV InfectionA virologic and fibrotic disease


13 janv. 2011

Tableau noir du cancer

Toutes et tous Tous


13 janv. 2011


Toutes et tous Tous


13 janv. 2011


Toutes et tous Tous


13 janv. 2011

Plan

• Natures

• Prévalence

• Facteurs de contamination

• Facteurs de gravité: vitesse de progression de la fibrose

7


13 janv. 2011

Différentes natures de l’ Hépatite C

• Historique

• Emotionnelle

• Rationnelle

• Economique

8



13 janv. 2011

Case 1: Mlle Koretz-Seef née Optimiste

• 85 ans

• Transfusée âge de 10 ans

• HIV négative

• Pas d’alcool

• Pas de diabète

• A0 F1

10


13 janv. 2011

Case 2: Mr Pitié-Salpêtrière né Pessimiste

• Mort à 40 ans

• Hémophile infecté à l’âge de 30 ans

• HIV positif

• Alcool 60g par jour

• Diabétique

• A3 F4, Carcinome Hépatocellulaire

11


13 janv. 2011

Prevalence of extra-hepatic manifestations

0

15

30

45

60

HCV n=1614 Control n=412

FatigueArthralgiaParesthesiaMyalgiaPruritusSicca syndromHypertensionDiabetesRaynaudThyroiditisPsoriasis

Cacoub, et al Arthritis Rheum 1999 Poynard, et al J Viral Hepatitis 2001


13 janv. 2011

Plan

• Natures

• Prévalence: Monde, France



13


F4

F1

F0

Fibrotic Liver Disease

F2

F3

Hemorrhage Liver failure Cancer

Poynard Lancet 1997


13 janv. 2011

Insulin resistance

Alcool consumption

Hepatitis B

Hepatitis C

Hemochromatosis

0 150 300 450 600

No advanced fibrosis Advanced fibrosis

15

Population at risk of liver fibrosis, cirrhosis and hepatocellular carcinoma (Millions)


Chronic Hepatitis C:180 Millions Worldwide


13 janv. 2011

Genotype

1,2,3

4

5

6

3

2


clinicaloptions.com/hepatitisHighlights From AASLD 2010

Regional Distribution of IL28B rs12979860 CC Genotype

Thomas DL, et al. Nature. 2009;461:798-801. Reprinted by permission from Macmillan Publishers Ltd:


13 janv. 2011

Mortality 2002Chronic liver disease (HBV, HCV)

• 1 death out 40 worldwide due fibrotic liver

• HBV 30% HCV 27% 929 000 / 1,6 millions

• Death: HCV 366 000 HBV 563 000

• Cancer HCV 155 000 HBV 328 000

• Cirrhosis HCV 211 000 HBV 235 000

Perz J Hepatol 2006

19


Perz J Hepatol 2006

HCC were attributable to HBV and HCV. Regionalestimates of the alcohol-attributable fractions were alsoconsistent with our estimates. Reported alcohol-attrib-utable fractions were generally high where viral hepati-tis-attributable fractions are low, and vice versa. It haspreviously been noted that alcoholic cirrhosis may pre-dominate in areas with low prevalences of HBV andHCV infections and be associated with a high propor-tion of HCC cases [8]. However, co-morbidity fromalcohol abuse and HBV and/or HCV infection is sub-stantial in certain regions and future e!orts to character-ize the burden of end-stage liver disease should aim at amore integrated accounting of these and other riskfactors.

Additional limitations in our study stem from issuesrelated to sampling, classifying and testing liver diseasepatients. In general, we found that the quality and quan-tity of studies appropriate for our analysis was loweramong cirrhosis patients relative to HCC patients, whileresource poor regions tended to have fewer well-suitedstudies available for inclusion overall. Such regionsmight have less reliable diagnostic tools available to cli-nicians and researchers (for viral hepatitis testing andfor the diagnosis of cirrhosis and HCC). Another con-cern relates to the fact that we utilized serologic testresults exclusively to classify subjects as HBV or HCVinfected, rather than considering the results of nucleicacid testing when available. This might have resultedin a degree of under-ascertainment of HBV- or HCV-re-lated cases [103], but was necessary to assure a uniformapproach.

Our findings help illustrate the great need for pro-grams aimed at preventing HBV or HCV transmission.In 1992, WHO recommended that all countries includehepatitis B vaccine in their routine infant immunizationprograms. As of 2003, WHO/UNICEF estimated 42%hepatitis B vaccination coverage among the global birth

cohort [106]. Therefore, implementation of this strategy,which represents the most e!ective way of preventingchronic HBV infection and related end stage liver dis-ease, is far from complete [107,108]. Other key primaryprevention strategies include screening blood donorsand maintaining infection control practices to preventthe transmission of healthcare-related HBV and HCVinfections [105,109,110]. In countries where these activi-ties have not been fully implemented, they should be giv-en a high priority. In most developed countries, injectiondrug use and high-risk sexual behaviors represent themajor risk factors for HCV infection and HBV infec-tion, respectively, indicating the importance of relatedprevention e!orts (e.g., reducing the numbers of new ini-tiates to injection drug use).

The role of programs to identify, counsel, and pro-vide medical management for the many personsalready infected with HBV or HCV requires carefulconsideration [105,110]. Counseling that includesadvice regarding avoidance of alcohol and educationregarding modes of transmission can help reduce therisks for developing chronic disease or spreading infec-tion to susceptible persons. The widespread applicationof therapeutic interventions also has the potential toaccelerate the declines in end-stage liver disease thatwill eventually follow from hepatitis B vaccinationand other primary prevention e!orts [104,107]. Recentadvances have occurred in the therapeutic managementof chronic hepatitis B and chronic hepatitis C, buttreatments are long and involve substantial costs andside e!ects [111–113]. Countries will need to considerthe potential benefits of treatment while insuring thatscarce healthcare resources are allocated in a mannerthat does not undermine primary prevention e!orts[114].

The relative contributions of HBV and HCV to end-stage liver disease are subject to temporal trends and

CIRRHOSIS HEPATOCELLULAR CARCINOMA

0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100%

EMRO-D

WPRO-B

WPRO-A

EMRO-B

AFRO-D/E

EURO-B/C

SEARO-B

EURO-A

AMRO-A

SEARO-D

AMRO-B/D

HBV

HCV

WPRO-A

WPRO-B

SEARO-D

EMRO-D

EMRO-B

EURO-B/C

AFRO-D/E

AMRO-A

AMRO-B/D

SEARO-B

EURO-A

HBV

HCV

a b

Fig. 1. Estimates of the attributable fractions of cirrhosis and hepatocellular carcinoma due to infection with HBV or HCV, by region.

J.F. Perz et al. / Journal of Hepatology 45 (2006) 529–538 535

Chine

Europe


4682 patients

180 HIV-HCV701 Alcohol812 HBV

382 Hemochromatosis2313 HCV 93 Steatosis BMI>25200 PBC

Poynard et al J Hepatol 2003


13 janv. 2011

Prevalence Anti-VHC France

• 1994: 575.000 (500.000-650.000)

• 2004: 370.000 (270.000-470.000)

• 2014: 270.000 ?

INVS www.2007, Dubois Hepatology 1997

22


http://www.2007

http://www.2007

13 janv. 2011

Infection chronique: PCR+ / Anti-VHC+

• 1994: 81% 460.000

• 2004: 65% 240.000

• 2014: 50% 135.000 ?

23


13 janv. 2011

“Connaissance du statut sérologique”

• 1994: 24% 137.000

• 2004: 56% 207.000

• 2014 ? 75% 202.000

24


13 janv. 2011

Traitement: 2002-2005

• 54.200 Traités

• 33.600 Naif

• 20.600 Non naif

• 13.500 par an

Deuffic et al J Hepatol 2008

25


13 janv. 2011

Mortality in France: HCV and HBV

• Deaths associated HCV 3618

• Deaths attributed HCV 2646

26

Marcellin et al Journal of Hepatology 2008


13 janv. 2011

S. Deuffic-Burban et al Journal of Hepatology 2008

HCV related mortality and treatment impact


13 janv. 2011

Mortality 2001 World vs France (1% of world)Chronic liver disease (20% HCV of liver)

0

0,375

0,750

1,125

1,500

All liver HCV

0,120

0,600

0,160

0,800

Cirrhosis Liver cancer

0

3 500

7 000

10 500

14 000

All liver HCV HCV Marcellin HCV Deuffic00

1 200

6 000

3 3002 646

1 600

8 000

World (Million) France


13 janv. 2011

S. Deuffic-Burban et al Journal of Hepatology 2004


13 janv. 2011

1994-2014

HCV-Ab PCR+ Informed Treated Cured Dead


13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

1994 2004 20140

150 000

300 000

450 000

600 000



13 janv. 2011

1994-2014

Treated Cured Dead


13 janv. 2011

1994-2014

1994 2004 20140

37 500

75 000

112 500

150 000

Treated Cured Dead


13 janv. 2011

1994-2014

1994 2004 20140

37 500

75 000

112 500

150 000

Treated Cured Dead


13 janv. 2011

1994-2014

1994 2004 20140

37 500

75 000

112 500

150 000

Treated Cured Dead


13 janv. 2011

1994-2014

1994 2004 20140

37 500

75 000

112 500

150 000

Treated Cured Dead


13 janv. 2011

Plan

• Natures

• Prévalence



32


13 janv. 2011

Dépistage: Discussion

• IVDU: 70%

• Non transfusés Non IVDU: 28%

• Elargir dépistage

33


13 janv. 2011

Risque élevé: Exposition au sang

• Transfusion avant 1991

• Hémophiles transplantés, hémodialysés, gammaglobulines, chimiotherapies

• Injection drogue intra-veineuse

• Personnel de santé avec accidents d’exposition au sang

• Enfants nés mère infectée HCV surtout si coinfection HIV

34


13 janv. 2011

Risque modéré: Exposition au sang

• Comportement sexuel à risque

• Infection herpes simplex 2

• Cocaine et paille

• Médical: chirurgie, endoscopie, dents ...

• Para-médical: acupuncture, sclérose...

• Autres: tatouage, piercing, bagarre...

35


13 janv. 2011

Risque nul ?

• Urines

• Selles

• Sécrétions vaginales

• Sperme ?

• Moustiques

• Tiques ??

36


13 janv. 2011

Plan

• Natures

• Prévalence



37


13 janv. 2011

HCV and Fibrosis: Stellate, Inflammatory and Apoptotic Cells

Feld Hepatology 2006


13 janv. 2011

HCV proteins and Fibrosis, Inflammation, Steatosis, Apoptosis

Shuppan Cell Death Differ 2003


13 janv. 2011

Survival of truth in HCV natural history

• 1980-1990: Necrosis biopsy, ALT

• Chronic persistent or active

• 1990-2000: Fibrosis biopsy

• Scheuer, Knodell-Ishak, METAVIR

• 2000-2010: Non invasive markers

• FibroTest, FibroScan…

40


F4

F1

F0


F2

F3


Poynard Lancet 1997


F4

F1

F0


F2

F3


No sexNo alcoholNo sugar

No fat No drug

Poynard Lancet 1997


F4

F1

F0


F2

F3



No fat No drug

HBV vaccination

Poynard Lancet 1997


F4

F1

F0


F2

F3



No fat No drug

HBV vaccination

ScreeningTreatment

Poynard Lancet 1997


FibroTest

F4

F1

F0


F2

F3



No fat No drug

HBV vaccination

ScreeningTreatment

Poynard Lancet 1997


13 janv. 2011

Fibrosis progression estimates : Methods

• Fibrosis estimate:

• « Observed »: 2 biopsies,

• « Estimated »: 1 biopsy,

• Time estimate:

• Between biopsies: short, bias, small sample

• Time of infection to biopsy: variability

• Age at biopsy = age at infection + infection duration

• Type of association between time and fibrosis:

• Linear, exponential…

• Time dependent : hazard function

• Markov transition

42


13 janv. 2011

Fibrosis progression modeling

• Poynard Lancet 1997

• Kenny-Walsh NEJM 1999

• Poynard J Hepatol 2001

• Westin JVH 2002, Deuffic JVH 2002

• Ghany Gastroenterology 2003

• Wright Gut 2003, Poynard J Hepatol 2003

• Ryder Gut 2004, Yi JVH 2004

• Thein Hepatology 2008

• Davis Gastroenterology 2010

43


13 janv. 2011

0

1

2

3

4

0 10 20 30 40 50

Stage Fibrosis METAVIR

Duration in years

Rapid fibroser

Slow fibroser

Poynard et al Lancet 1997

Dynamic Concept: Fibrosis progression rate

Intermediate fibroser


13 janv. 2011

Poynard et al Lancet 1997

0

1

2

3

4

0 10 20 30 40 50

Duration in years

Male, > 40y, > 50 g alcohol

Female, < 40y, < 50 g

Stage Fibrosis METAVIR


2313 patients

>50 n=14941-50 n=211

31-40 n=348

21-30 n=851

<21 n=754

Poynard T et al. J Hepatol 2001


13 janv. 2011

Annual Stage-Specific Transition Probabilities in Individuals with Chronic Hepatitis C Virus Infection

Fibrosis Stage Estimate Mean (95% CI)

F0-F1 0.109 (0.107, 0.110)

F1-F2 0.068 (0.067, 0.069)

F2-F3 0.113 (0.110, 0.116)

F3-F4 0.125 (0.120, 0.130)

• Thein Hepatology 2008


Gary L. Davis, Miriam J. Alter, Hashem El-Serag, Thierry Poynard,

Linda W. Jennings, Gastroenterology 2010

Age at infection, Gender, Duration Infection


13 janv. 2011

HCV Cirrhosis prevalence in USA

Davis et al, Gastroenterology 2010jeudi 13 janvier 2011

13 janv. 2011

Factors associated with fibrosis progression in HCV

Sure

• Fibrosis stage

• Age (Duration)

• Alcohol >50g/d

• HIV

• CD4 <200/ml

• Male

• Necrosis

• BMI, Steatosis,Diabetes,

• Schistosomiasis

Not sure

• Inflammation

•Hemochromatosis hH

•Cigarette, Cannabis

•Alcohol <50g/d

•HBV

•Transplantation

•Genotype 3

Poynard et al Lancet 2003, EASL 2004

Not associated

•Last viral load

•Genotype non-3

•Mode of infection


13 janv. 2011

Expression of liver steatosis in HCV infection and pattern of response to interferonLiver steatosis in a patient genotype 3 with recurrent hepatitis C after transplantation

Rubbia-Brandt et al, J Hepatol 2001

Before therapy Response Relapse


13 janv. 2011

Effect of HCV Treatment on SteatosisGenotype Non-3

0

20

40

60

80

Sustained Responders n=461 Non Responders n=439

Before After

Poynard et al Hepatology, 2003


13 janv. 2011

0

25

50

75

100


Effect of HCV Treatment on Steatosis Genotype 3

Before After



13 janv. 2011

0

25

50

75

100


Effect of HCV Treatment on Steatosis Genotype 3

Before After

Viral Steatosis



13 janv. 2011

Poynard circa 1990

Patients are seen 15 years after Infection

« Qui a fibrosé fibrosera »

« Who had fibrosed will fibrose »

54


13 janv. 2011

Risk of errors : Florilege

• Good estimates with good quality biopsy

• ALT is very useful for clinician to predict fibrosis progression

Ghany Gastroenterology 2003


13 janv. 2011

Area of fibrosis estimated by biopsy according to its length (mm) in subjects scoring METAVIR F0 (no fibrosis) on large surgical section.

!

Area of fibrosis >5.3%: false positives of biopsy for the diagnosis of advanced fibrosis Cases >10.1%: false positives of biopsy for the diagnosis of cirrhosis.


13 janv. 2011

Risk of errors : Florilege

• Good estimates with good quality biopsy

• ALT is very useful for clinician to predict fibrosis progression

Ghany Gastroenterology 2003


13 janv. 2011

Annual cost of Hepatitis C: US $

• No complications 110

• Ascites refractory 18 730

• Variceal bleeding 19 127

• Encephalopathy 12 278

• HCC 32 995

• Transplantation 108 650

Wong et al. Am J Public Health 2001

58


Poynard BMC Gastro 2010








FibroTest!First Line!

Reference Center FibroScan for!Confirmation !

Biopsy!If discordances!



13 janv. 2011

Population générale n=7.395 > 40 ansFacteurs Indépendants (P<0.005) de risque de Fibrose F234 (3%)présumée par FibroTest

60

Odds Ratio


R2=0.35


13 janv. 2011


0

5

10

15

20

Male Age Tour Taille Glycémie Alcool CDT HCV

60

Odds Ratio


R2=0.35


13 janv. 2011


0

5

10

15

20

1,12

4,3

1,03 1,15 1,8

18

Male Age Tour Taille Glycémie Alcool CDT HCV

60

Odds Ratio


R2=0.35


13 janv. 2011

Résumé (1): Histoire naturelle de la fibrose

• Grossière linéarité par décades avec une accélération progressive après 40 ans

• Confirmation

• du rôle majeur de l ’âge

• de l’alcool > 50 g

• de l’insulino-résistance (diabète, surpoids, stéatose)

• HIV

• Absence d ’association

• Mode de contamination, génotype non-3, dernière charge virale

61


13 janv. 2011

Résumé (2): Mortalité

• Tueur lent et silencieux

• Deux sujets contaminés sur trois exposés à un risque majeur

62


13 janv. 2011

Résumé (3): Hépatite C en France

• 220.000 contaminés

• 4.000 morts / an (en augmentation)

• 50 % détectés

• 25 % traités

• Le traitement guérit plus de 70% des sujets et freine la progression de la maladie chez les autres

63


13 janv. 2011

Conclusion:

Dépister plus
